Standard BioTools Releases Financial Performance for Q3 2025

November 4, 2025 - 20:32

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 -- Standard BioTools Inc. has announced its financial results for the third quarter ending September 30, 2025. The company reported a total combined revenue of $46.2 million for the quarter, with revenue from continuing operations reaching $19.6 million.

In a strategic move to enhance operational efficiency, Standard BioTools has implemented a comprehensive restructuring plan aimed at generating over $40 million in annualized cost savings. This initiative is part of the company's broader strategy to streamline operations and improve financial performance.

Furthermore, the company is on track to achieve its target of positive adjusted EBITDA, reflecting its commitment to financial health and sustainability. These results underscore Standard BioTools' efforts to navigate the evolving market landscape and position itself for future growth. The company remains focused on delivering value to its stakeholders while adapting to the challenges and opportunities within the biotechnology sector.